Lillys eloralintide (amylin receptor agonist), providing a potential option for Lilly to defend against amylin analogues, including Novo Nordisks CagriSema, which combines dual amylin and calcitonin receptor agonist cagrilintide and semaglutide, or Zealands petrelintide (phase 2) Structure Therapeutics GSBR-1290 (GLP-1), small molecule, oral obesity therapy, seeking to substantiate its earlier, positive phase 2a data to deliver competitive weight loss, against both other oral therapies and marketed injectables, with acceptable tolerability (phase 2b) Crucially, a number of phase 3 readouts in 2025 for key AOM assets will set the stage for their launch in 2026, when the next wave of AOMs enter the market to re-shape the competitive landscape: Lillys orforglipron (GLP-1), one of the first oral AOMs to launch, possibly alongside oral semaglutide, and when it does, the first small molecule based therapy in the market
References Maquart, F
For example, some patients need blood sugar and insulin stability to be their first priority for treatment
You found this not helpful 0 of 0 found this helpful Berzo226 Verified Buyer First time using after doing the research on how it benefits with weight loss
For complete step-by-step visual guides specific to each medication, see our dedicated reconstitution articles: how to reconstitute 5mg semaglutide , the full semaglutide reconstitution guide , and how to reconstitute tirzepatide
While GLP-1 agonists work well for controlling blood sugar and helping with weight loss, its important to remember that they arent suitable for everyone, including pregnant individuals or those with certain pre-existing health conditions, like a history of pancreatitis